



www.ncpanet.org *The Voice of the Community Pharmacist*®

Follow us on social media



Specialty Pharmacy: A Data-Driven Success Story

Jake Olson, Pharm D.
President/CEO Skywalk Pharmacy
Children's Hospital of Wisconsin

#NCPA2017
www.ncpanet.org/convention



Disclosure

Jake Olson, Pharm D., President/CEO Skywalk Pharmacy declares no conflicts of interest or financial interest in any product or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.

#NCPA2017
www.ncpanel.org/convention



Learning Objectives

- Discuss key data elements necessary to build a value proposition for payers.
- Discuss packaging data for your patients and using data to create a compelling story for your services.

#NCPA2017
www.ncpanel.org/convention



Agenda

- Outcomes definitions
- Accreditation
- Payer Networks
- Manufacture/LDD Access

#NCPA2017
www.ncpanet.org/convention



Stages of Specialty Pharmacy Growth

- (1) No SP capabilities—possibly outsourced to another company?
- (2) Neophyte SP with limited capabilities—pharmacy services just started, 1-2 disease states, in service <1 year
- (3) Immature SP but growing capabilities—3-5 disease states, in service at least 1 year, some data and reporting capabilities
- (4) Near standard SP services—6-8 disease states, centralized SP, in service >2 year, good reporting capabilities, 1-2 payer contracts, 1-2 LDD
- (5) Mature fully functioning SP—all disease states, centralized SP—likely off-site, all systems in place, multiple payer contracts, multiple LDD (very few at this level)

#NCPA2017
www.ncpanet.org/convention



Pharmacy Profitability Examples

	AWP-18%	AWP-22.5%	NADAC (WAC - 3.4%)	Purchasing WAC - 5%
Wholesale Acquisition Cost	\$ 4,441.23	\$ 4,441.23	\$ 4,441.23	\$ 4,441.23
Average Wholesale Price (AWP = WAC + 20%)	\$ 5,329.48	\$ 5,329.48	\$ 5,329.48	\$ 5,329.48
Reimbursement from Payer (AWP - X%)	\$ 4,370.17	\$ 4,130.35	\$ 4,290.23	\$ 4,290.23
Purchase Price from Manufacturer or Wholesaler (WAC-2.75%)	\$ 4,319.10	\$ 4,319.10	\$ 4,319.10	\$ 4,219.17
Dispensing Fee	\$ 1.00	\$ 1.00	\$ 12.00	\$ 12.00
Gross Margin	\$ 52.08	\$ (187.75)	\$ (16.87)	\$ 83.06
Gross (% of WAC)	1.2%	-4.2%	-0.4%	1.9%
Reimbursement BI/BV Cost/RX	\$ (21.00)	\$ (21.00)	\$ (21.00)	\$ (21.00)
Patient Services Cost/Rx	\$ (5.00)	\$ (5.00)	\$ (5.00)	\$ (5.00)
Cost of Dispensing	\$ (11.00)	\$ (11.00)	\$ (11.00)	\$ (11.00)
Net Profit \$/Rx	\$ 15.08	\$ (224.75)	\$ (53.87)	\$ 46.06
% of WAC	0.3%	-5.1%	-1.2%	1.0%

Reimbursement (BI/BV) cost assumes 30mins/Rx @ \$30/hr; and 30 minutes for PA on 50% of Rx's

Patient services cost assumes 15 min/Rx at \$20/hr




#NCPA2017
www.ncpanel.org/convention

NCPA
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

The ECHO Model

- Evaluation of the effect of Health Care Interventions on patient-related outcomes

- Economic
- Clinical
- Humanistic
- Outcomes



#NCPA2017
www.ncpanel.org/convention

NCPA
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

Economic Outcomes

- Patient Assistance/Copay Assistance
- Cost per prescription
- Total cost by category/class
- Per member per month costs
- Cost Avoidance



#NCPA2017
www.ncpanet.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

Clinical Outcomes

- Medication possession ratio (MPR)
- Proportion of Days Covered (PDC)
- Adverse Events
- Disease Specific
 - Sustained virologic response (SVR) for Hep C
 - Exacerbations for MS
 - FEV1 for CF



#NCPA2017
www.ncpanet.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

Humanistic (Operational/Service) Outcomes


- Call center statistics
 - Speed to answer
 - Abandonment rate
- Error Rates
- Time to fill
- Turnaround time
- Patient satisfaction



#NCPA2017
www.ncpanet.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

Stakeholders for Outcomes



#NCPA2017
www.ncpanet.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

Considerations for Outcomes

- Who is the audience/stakeholder?
- Are there benchmarks?
- What are your competitors reporting?
- What are your differentiators?
- Can you retrieve the required data to report outcomes?
 - Is it in a reportable format?
 - Do you have the required IT infrastructure and resources?

#NCPA2017
www.ncpanet.org/convention




Challenges with Outcomes

- Do I have enough?
- There are often no benchmarks
- The important data outcomes will vary by recipient
- The data needed will often be in multiple systems and may be challenging to obtain
- There will need to be dedicated resources assigned to managing the data to report outcomes

#NCPA2017
www.ncpanet.org/convention





So where do I start?

- Tools
 - Pharmacy Operating System
 - Medication Synch/scheduling software
 - Excel Spreadsheets for PA management
 - Reporting software companies
 - Communication software (notes in baskets aren't going to cut it)
 - Clinical software platform

#NCPA2017
www.ncpanel.org/convention

NCPA
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

Specialty Pharmacy Data Elements

- New/Refill Prescription numbers
- Profit margin per Rx (drug, payer, overall)
- Broken down by therapeutic category
- Patient numbers per drug, payer, prescriber
- Pull out numbers from traditional business

#NCPA2017
www.ncpanet.org/convention



Accreditation

- In 2016, Specialty Pharmacy Times reported that, “if a pharmacy wants to have access to limited-distribution products and payer coverage, accreditation is near mandatory”
- PBM contracts requiring 2 accreditations, 1 of which must be URAC
- Other accreditations
 - ACHC
 - JCAHO
 - CPPA
 - VIPPS
- URAC 3.0 focuses on a case manage approach to patient management
- Only about 1/3 of the pharmacies with URAC accreditation have achieved the 3.0 standards to date

#NCPA2017
www.ncpanet.org/convention



What Data is required for accreditation?

- As of 2016, measures must be submitted through a certified vendor and externally audited for validity by an independent third party.
- Organizations must enter into service agreements directly with the accreditation companies allied software vendor, and audit vendor
- Luckily this is free (sarcasm font)



#NCPA2017
www.ncpanet.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

What Data is required for accreditation?

Provide for All Patients:

–A consistent, overarching patient care process that includes for example:

- Patient onboarding
- Past medical history
- Medication history
- Drug allergy check
- ADR documentation including FDA reporting

–Patient interventions including

- Drug problems identified
- Who was notified?
- What was recommended, accepted?
- Ultimate outcome and any hard or soft cost savings?

–Pharmacy must have evidence of

- Initial assessment
- Follow up assessment(s)— ideally the next month, but may be later depending on the program design

–Program must measure

- Total patients on that therapy in the pharmacy
- Total patients who opted in to the program and the number who opted out

#NCPA2017
www.ncpanet.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

What Data is required for accreditation?

- Drug-Drug Interactions
- Call Center Performance
 - Response rate
 - Abandonment rate
- Dispensing Accuracy
 - Incorrect drug or product dispensed
 - Incorrect recipient
 - Incorrect strength
 - Incorrect dosage form
 - Incorrect instructions
 - Incorrect quantity
- Distribution Accuracy
 - Drugs or products dispensed with incorrect patient address
 - Drugs or products dispensed with correct address but delivered to wrong address
- Turnaround Time for Prescriptions
 - Turnaround time for clean prescriptions
 - Turnaround time for prescriptions requiring intervention
 - Turnaround time for all prescriptions
- Proportion of Days Covered (PDC)
- Fulfillment of Promise to Deliver
- Primary Medication Non-Adherence
- Consumer Experience with Pharmacy Services

#NCPA2017
www.ncpanet.org/convention



Patient Satisfaction Data

- Zitter Health Patient Surveys
- NASP Patient Satisfaction Survey
- Levels the playing field with comparisons between different SP
- Accreditation Requirement

General Survey Content
Patient demographics
Specialty Pharmacy benchmarking
How the patient was acquired and uses the specialty pharmacy
Reimbursement Services/Formulary challenges and their impact in affordability
Specialty Pharmacy and Patient interaction
Patient: First Fill experience/Re-fill experience
Net Promotor Score of the Specialty Pharmacy and patient loyalty
Customer service of various facets/roles within Specialty Pharmacy
Patient plan/benefit design
Specialty Pharmacy switching

Zitter Health Insights • © 2015 All rights reserved

#NCPA2017
www.ncpanet.org/convention



Value of Accreditation for Improving Operational and Patient Outcomes

Operational

- Quality and Performance improvement requirements
 - Can improve service levels and efficiencies
 - Can save expenses
 - Labor
 - Shipping
- Metrics
 - Measure to manage
 - Improving
 - Declining
- Adherence to regulations
 - HR requirements
 - Licensing requirements

Patient Outcomes

- Initial Assessment Requirements
 - Baseline information gathering
- Follow up Assessment Requirements
 - Compliance, Adherence, Persistency
 - Adverse Events
 - Quality of Life
- Care Plans
 - At risk patient identification
 - Collaboration with other Healthcare providers
- Education Requirements
 - Patient education
 - Literacy levels
 - Cultural

#NCPA2017
www.ncpanel.org/convention



WHY Outcomes Are Important to the Payer

- Cost Containment
 - Healthcare costs in line with company growth, revenue and projections
 - Sustainable benefit structure
- Improved Quality of Care
 - Evidence of effective treatment regimens (Did they get what they paid for?)
- Mitigation of future medical bills
 - Did proactive pharmacy spend prevent future medical spend?
- Productive workforce
 - Reducing absenteeism
 - Improved Quality of Life
- Employee satisfaction and retention

#NCPA2017
www.ncpanel.org/convention




What Data is the Payor Requiring?

- Top 5 questions from Payers
 - Is the treatment working and is the patient adherent to therapy? – Clinical Outcomes
 - How long has the patient been on therapy?
 - Is the patient receiving high quality services?
 - Were prior authorization steps taken?
 - How many patients will be receiving therapy?
- Patient surveys
- Time on Therapy
- Disease Specific analysis
- Summary Utilization
- Reauthorization
- Time-to-fill
- Patient Abandonment and Rejection Rate
- Patient Assistance
- Patient status (PA, Shipment, Hold, etc.)

#NCPA2017
www.ncpanet.org/convention



Inclusion in Payor Network



#NCPA2017
www.ncpanet.org/convention



No data

Unhappy Drug Rep and HUB

No prescriptions

#NCPA2017
www.ncpanel.org/convention

NCPA
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

HUB Vendors

#NCPA2017
www.ncpanel.org/convention

NCPA
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

How Network Partners Are Chosen

Channel Access To Drug		Level of Control	
Open	Preferred	Limited	Exclusive
<ul style="list-style-type: none"> > 100k patients Low control Low touch service No data visibility No limit on access 	<ul style="list-style-type: none"> 100k – 20k patients ↑ control Low touch service ↑ data visibility No limit on access; list of preferred partners 	<ul style="list-style-type: none"> 20k – 5k patients ↑ control Medium touch service ↑ data visibility 1 SPP/\$1,000 drug cost 1 SPP/100 patients/month 	<ul style="list-style-type: none"> < 5k patients High control High touch service High data visibility 1 SPP

These networks can vary by drug AND by type of site of care

#NCPA2017
www.ncpanel.org/convention



Dispensing Entity Decisions


<p>PAYER ALIGNED</p>	<p>RETAIL ALIGNED</p>	<p>WHOLESALE ALIGNED</p>	<p>INDEPENDENT</p>	<p>HIS / IDN / ACO</p>
-----------------------------	------------------------------	---------------------------------	---------------------------	-------------------------------

ALIGNMENT AFFECTS OBJECTIVES, BEHAVIOR, and WILLINGNESS TO PARTNER

#NCPA2017
www.ncpanel.org/convention



What does the manufacturer want to hear for inclusion into their LDD network?



#NCPA2017
www.ncpanel.org/convention

* AMCP JMCP 2015 adherence reports
** Surescript article August 2016



Other LDD Access "folks" to consider

- Medical Science Officer
- Marketing Department
- HUB
- Wholesaler
- Data aggregator

#NCPA2017
www.ncpanel.org/convention



Types of Manufacturer Contracts

- Manufacturer data contracts
 - Access to product
 - Rebates to the pharmacy
 - Rebates to the payers
 - Fair Market Value service contracts
 - GPO contracts

#NCPA2017
www.ncpanet.org/convention



Legal Issues play a role

- Anti-Kickback Statute
- Stark Law
- Civil Monetary Penalty Law
- HIPAA
- Medicaid Best Price, AMP and ASP price reporting
- Core Services vs. Enhanced Services
 - Establishing FMV and commercial reasonableness
 - Discounts vs. Payments
 - Evidencing Performance of Services


#NCPA2017
www.ncpanet.org/convention



HIPAA plays a role

- Patient level data integration
 - No PHI
 - No chance of data breach and easy legal and compliance review
 - Low quality data. Inaccurate patient counts and length of Tx
 - Partial PHI
 - Only send data for patient with signed HIPAA auth/consent
 - Risk for manufacturer if SP doesn't have proper forms for each state
 - Full PHI
 - Best data set, but need stakeholder alignment
 - Check your POS/switch contracts

#NCPA2017
www.ncpanel.org/convention




#NCPA2017
www.ncpanel.org/convention



Bona-Fide Service Fees

• Per § 414.802, the considerations to be met for a service fee paid by a manufacturer to an entity to be bona fide and excluded from ASP calculation:



***Per CMS, "if the fee paid meets the other elements of the definition of 'bona fide service fee', then the manufacturer may presume, in the absence of any evidence or notice to the contrary, that the fee paid is not passed on to a client or customer of any entity" (72 Fed. Reg. 39164 (Jul. 17, 2007))

BLUE FIN GROUP 

#NCPA2017
www.ncpanel.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

What Data is the Manufacturer Requiring?

- Patient Onboarding Data
 - Referral volume for their drug
 - Stages of approval:
 - Rx Received – Benefits Investigation - PA? - Deny? - Appeal? - Overturn?
 - Time between each stage
 - Overall time from receipt to dispense
 - Success rate:
 - ☐% dispensed by your pharmacy
 - ☐% referred out and to whom?

#NCPA2017
www.ncpanel.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

What Data is the Manufacturer Requiring?

- Patient “Clinical” Data
 - Adherence and Persistency
- MPR (medication possession ratio)
- PDC (proportion of days covered)
- Pharmacovigilance
- REMS data
- Quality of Life
- Disease progression
- Inventory Levels
- Payors (Insurance, Medicaid, Copay assistance, Copay to member)



#NCPA2017
www.ncpanet.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

Setting Standards for data transmissions

- NCPDP workgroups
- WG7 = Manufacturer and Associated Trading Partner Transaction Standards
- Phone calls every other week
- Quarterly meetings in various locations
- <https://www.ncdp.org/Events/Work-Group-Meetings>

#NCPA2017
www.ncpanet.org/convention

NCPA®
NATIONAL COMMUNITY
PHARMACISTS ASSOCIATION

Jake Olson, Pharm D.

President/CEO Skywalk Pharmacy

jake@skywalkpharmacy.com

#414-337-3343

#NCPA2017
www.ncpanel.org/convention

